ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Industry Groups Lobby for Lower Standards for FDA Approval

November 18, 2011

CT Finds Early Lung Tumors In Smokers, Former Smokers

March 31, 2006

Gallo, Rosenberg, Bishop, Varmus Win GM Awards

June 15, 1984

FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer

January 28, 2005

FDA Encourages Study Of Gender Differences

August 6, 1993

Dose Dense Chemo Study Published Early; Method Improves Breast Cancer Survival

February 28, 2003